# An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer

Source: https://onco.cc/trials/nct06938282/  
OnCo record `nct06938282` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by Shanghai Zhongshan Hospital, now recruiting.

## Summary

An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer is a phase 2, interventional study registered as NCT06938282 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 60 participants, started 2025-06-23 and due to reach its primary completion in 2027-04-30. Interventions recorded: HRS-4642. Conditions listed: Pancreatic Cancer. Primary outcome: Adverse events (AEs); Arm 1:Objective Response Rate (ORR); Arm 2:18m-OS rate. Pancreatic eligibility wording from the registry: "Pathologically or cytologically confirmed ductal adenocarcinoma of the pancreas; and subjects must have at least one measurable lesion as defined by RECIST v1". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06938282
- Phase: 2
- Setting: An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer
- Sponsor: Shanghai Zhongshan Hospital
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06938282: https://clinicaltrials.gov/study/NCT06938282

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06938282.json